Neurology

FDA approves donanemab, first new Alzheimer’s drug in nearly two years

The U.S. Food and Drug Administration has approved donanemab, a treatment for people in the early stages of symptomatic Alzheimer’s disease. The decision ends a long wait for a new option in a field…